Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Mail & Guardian (Johannesburg) - September 17, 2003
Change of tune: South Africa's Medicines Control Council (MCC) has issued a statement stressing that the use of nevirapine for the prevention of mother to child transmission is not ôbannedö in South Africa, following the publication of full results from the controversial HivNet 012 study last Friday.
In July the MCC warned nevirapine's manufacturer, Boehringer-Ingelheim, that the drug's approval would be rescinded in South Africa unless the company came up with additonal data to support a licence within 90 days.
The MCC was concerned that the standards of data collection in the HivNet 012 study were lax and that important safety information might be missing.
However, South African researchers protested that additional information was available, and called on the MCC to rethink its decision. The MCC has now revealed that it is discussing the data with researchers, and has extended the period allowed to Boehringer-Ingelheim to present further information.
030917
MG030911
Copyright © 2003 - Daily Mail & Guardian. For information about the content or for permission to redistribute, publish or use for broadcast, contact the publisher.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .